l l ! l "$#l ?

l l  l 

!#"l 

?

*6-$l 1978A53B0l 1978A53B

%'3#A)?/+.B

l 1982A57B ,579>:@A&'3B
Al 1986A61B !

+=8;><?4B(,579>:@A23?C'"01Bl 2004A16B


ACB

++

"&1l HIFIG)M%*3*3*3*3

'3=<l *?#Ml *>=C4JM7?/@negative selection?

0.(+8ED5=6;9!

*DAl $:6B32K?L?*'D->,74

,9;@<B?:=@>
'3&D19824(28EF4,"/)3+2?
F*G9(% 36"/)
31.,AAA

F-7(40C358!
#$+!

L5DF
1@PQSRT*-) 8UJCOG 8V
( *HHNK

0/9*U63;V#6

*U83;V

2%

*'<*

(,**1986
(W:K@PQSRT@GAOLG 7BPECI=4K7?J>?
$".1@PQSRTMU33&V 147
 453 1067 

503992>B @182B*KIT2004

DV50"WT
+1( %/$X
5 B
<=G6(L!X27I9E9:
http://www.nara-pho.jp/about/ 2019/4/24

,( 3B'
https://ja.wikipedia.org/wiki/%E8%AB%B8%E8%91%9B%E4%BA%AE 2019/4/24&#)$X
5QRSPON;?<= A=U6?4 E>HJE9:
-$X
5C0KJ:H.8FM;G6

https://www.med.nagoya-u.ac.jp/shinzougeka/staff/cat/usui.html 2019/4/24

# GK I188K/US^2004N`50%a^
07- )4(b; K
EFQ<-V$b
2=SAOAC@KVSF:K9,V'>=5M*A?OB
1- +&.(b;[\]ZYXDHEF J"F_<
H:# OG"RTOAC!2(b;L6UTCR3>PWDQ<' h 7OfZdYabYa
Wy}ce7^dp`lg}m~X
ll

B;-YIA?75 ,GJM2010'
B;<R 2010'
••••https://www.drsgate.com/company/c00043/ 2019/4/24

4(B;!

76S&]pt{u}l)
B;!

?532hL011@
TNMV/"jhv}ux}s. A40,000 
! h3! \n5! j
CED9|+*=D h<R2hT

B;K:
rqwzq{lCED92016')

W[k#_iF_om~X

76SN8!

https://www.jmedj.co.jp/journal/paper/detail.php?id=1161 2019/4/24

1PUHCQ>!
2018'

7%$!
http://www2.convention.co.jp/69jats/welcome.html 2019/4/24

:&9/7.45.4
!' (+" A :)#(*=671?> ?@,A+;- ?,http://www.jpats.org/modules/about/index.php?content_id=3 2019/4/24

1:8: .90?4
3:%9<?4289$l l  l 

!#"l 

?

*9DC5;6=A?H )0&,(-.#$ 8 :=)0 &seminoma@4E'E !E+% 1989;29:279-285

49E"173 2F/?>B<G––"2power9-)63,%'228 

Williams SD, Birch R, Einhorn LH, et al
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, andeither vinblastine or etoposide
N Engl J Med 1987 Jun 4;316(23):1435-40

$8#/64(→  CR

+!1

1.0*5

&176

3BA+4,5=:D1987

150C

1. !09/65>#)8OK9;:CCC
2. !)A&*(; ":%4@/?

l.2<8).?1l'9)A=7;!;$Radiology 1991;181:147-152

Accuracy•Mediastinal
invasion :76%
•Chest wallinvasion :100%

Adding pneumothorax CT to the staging procedure in lung cancer will allow
more appropriate treatment and provide more information for planning surgery!/87+0,163@ "4#%44< -$-cT2aN0M01988 "&)'? *:;9(: pT2aN1M1a'5#→ "7'304 2.

61#%"'=19POD>?' JThorac
CardiovascSurg2002;123:184-185
J Thorac
CardiovascSurg
2002;123:184-185
Our results
indicatethat carefully selected patients with carcinomatous

pleuritis may be candidates for extrapleural pneumonectomy for cure)54!*",30< 

0!*"12?
21  &$?
→'+%-(.#/8679&/$
86791
CAMP therapy:1988 ;• CDDP
20 mg/m2 x 4• ADM
40 mg/m2• Methy=prednisolone
1000 mg/body x 4
500 mg/body x 2

J Thorac Oncol 2007;2:73-78

CAMP

38 8
/D75?61+*8 4
III8Type B2

0

CAMPC=@>

• CAMP 4=@>• ),?),+.8
 BCV?SVC?-?
( 3• BCV-SVC
• #"&:;<CR• .'!$ 56Gy
• !$228
A2 (%9.BThe multimodality therapy containing this chemotherapy
is justifiable for the initial treatment of patients withadvanced thymoma32 Stage IVa
Type B2CAMP  +  (EPP) : 7 32
: 663g : Ann Thorac Surg 2009;88:952–957

Overall Survival

Recurrence-Free Survival

EPP as part of multimodality therapy for selected patients showed
a possibility of improving local control, leading to cureGrowing Teratoma Syndrome18 
Non-seminomatous
germ cell tumor
CDDP+Etoposide+BLM 4AFP 

Clamshell

ESTS Textbook ofThoracic Surgery, vol 2
Mediastinal Germ Cell Tumours,
p267-276   20  T3 5  %


Pitz
DowneyMagdeleinat
Facciolo
Burkhart
Matsuoka
Doddoli
2004
N0

N1

N2

Overall

36
49
25
67
44
44
40
49

23
27
20
100

14
15
21
18

24
32
24
61
39
34
31
43

26
40
24
36

6
821

9 10 !".'CAF
Concurrent ChemoradiotherapyB
+9CEF:)&DB D3;,/.'9 10 !"T3N0-1M0%
 &@PS 0-1@20-70
CDDP (80mg/m2) + VNR (20mg/m2 x 2) 2 GIH
Concurrent RT (40Gy)
+9J

&->=?57K*%L53J20093-201211@54(6K24<*L3$#J83$#L47%@3$#L67%K


0CDDP (80 mg/m2 day 1)
VNR (20 mg/m2 day 1, 8)
40Gy/20Fr

! 4812  31%CR  (n = 51)(("45658
(30-69)( #$( $CT!%'&(  IIB (T3N0M0)
IIIA (T3N1M0)

45
39
1140
1126
1510Kawaguchi K. Ann Thorac Surg 2014)98:1184


Completed
Incompleted ()PRSDPD ()




%

49
296
4

26
24
151
47
2

 (n = 48)






%

47
198
2

741

1585



 ()
1



166133132

(n = 48)
%



R0
R1R2

44
3
192
62



CR
Minimal residual

1231

25
65

122244

T4N2M1b
Minimal residual: viable cells 1/3   : 2%

Kawaguchi K, et al.

A prospective, multi-institutional phase II study of induction
chemoradiotherapy followed by surgery in patients with non-small celllung cancer involving the chest wall (CJLSG0801)
Lung Cancer 2017;104:79

76.5%
62.6%
62.6%

68.2%
68.2%

66.0%
66.0%

$cT3N0-1% "#&  * *!(!')3  +47%
316/51
 died+67%

17/51 recurred

OSPFSOS3+67%

PFS l l  l 

!#"l ?

!#? 

!#?



"#?
• •QOL$  • •" %




2006
63

 ? GGO? GGO

2006
63



#354*- ?6 GGO

201876PS 0•‘’/+•. 02•%.12 *"('1"('"?

•,!&) $"?


< 20
20-29
30-31
40-49
50-59
60-69
70-79
80-89
≥ 90?1 ,.-$&/20150%

')
490.1



0.08
• 32 (ADL)?
0.6•234)'!%+"#*?
J Thorac Oncol 2009;4:1247-1253
1,066
2.6
Octogenarian patients with c-stage I lung cancer in this study
had a satisfactory long-term outcome and low-mortality rate
3,716
9.2
13,27632.9
16,954
42.1
4,912
12.2
620.2

Gen Thorac Cardiovasc Surg 20182661581< 60  ≥ 80

Overall Survival

Cancer Specific Survival?

 2010 2004


IA

88.9

86.8



IB

76.7

73.9



IIA

64.1

61.6

IIB

56.1

49.8

IIIA

47.9

40.9

IIIB

30.2

27.8

IV36.127.9



Overall Survival2004 2010 6&7:IQN>?8#?R 60.7,%

5y-OS 5y-DFS
IA88.9'A$PHDQ:!3C2•••••$)"JFKGMEOL4
Supportive care=A



84.0

-4.9

IB76.7

65.0

-11.7

IIA

64.1

48.3

-15.8

IIB

56.1

44.1

-12.0






IIIA 47.9A/*<26.3-21.6
60.,%7@9;B+$A

Disease-Free Survival

IIIB

30.2

21.7

-8.5

IV

36.1

16.2

-19.9,%(120105"#'687,.%?< !
N = 235y-OS: 87.7%

Ann Thorac Surg 2014;97:1743–1749
/!',(42OS153.%•••

EPP188.69 &?
Over-surgery,1.%0&?
+-)42$*0
1?
84.59

OS!<115$EEP<8:7%;

EPP
N = 9:36%;
5y-DFS: 83.3%

• #E
C6

F2 01I01?;AF• >EEE D76@276A:K<BM*HK)95K
••
•
l



C.PNO/E#E+95K(Q$"Q!,M&=K)
'E% A-C9HJLK

8J3

4G





.9478;0:36 =Ambroise Paré, 1510-1590> ! "Je le pansai, Dieu le guérit"(+#,<
https://ja.wikipedia.org/wiki/2019/5/8

$  % %)=> $'"Guérir quelquefois, soulager souvent, consoler
toujours""Cure occasionally, relieve often, console always"

&"*$*-<152;
/28;2:152;
https://konishi-dental.tokyo.jp/katayama-seminar/edward-trudeau.html 2019/5/8

 


400

350





4293

2448

300

286

250

332


160

150

133

136

137

197
172

68

248

192

254

202

156

135
100

80

188

182

136

247

377

302

232

151

100
64

187

372

388

332

237

200

50

362

383

84

95

90

73

4502000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018%" #($&"14 10) !'% ! %"%"

http://nuh-forum.umin.jp/hospital/nagoya.html 2019/5/8